The Greenrose Holding Co (STU:50U) Debt-to-Equity: 9.76 (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:50U The Greenrose Holding Co STU:50U
22 GF Score
Price €2.36
View Full Analysis

What is The Greenrose Holding Co Debt-to-Equity?

The Greenrose Holding Co STU:50U 22 Debt-to-Equity is 9.76 as of Sep. 2022. GuruFocus rates STU:50U with a GF Score™ of 22/100.

The Greenrose Holding Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was €133.64 Mil. The Greenrose Holding Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was €9.67 Mil. The Greenrose Holding Co's Total Stockholders Equity for the quarter that ended in Sep. 2022 was €14.68 Mil. The Greenrose Holding Co's debt to equity for the quarter that ended in Sep. 2022 was 9.76.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for The Greenrose Holding Co's Debt-to-Equity or its related term are showing as below:

STU:50U's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.28
* Ranked among companies with meaningful Debt-to-Equity only.

The Greenrose Holding Co  (STU:50U) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

The Greenrose Holding Co Debt-to-Equity Related Terms

The Greenrose Holding Co Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for The Greenrose Holding Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Greenrose Holding Co Debt-to-Equity Chart

The Greenrose Holding Co Annual Data
Trend Dec19 Dec20 Dec21
Debt-to-Equity
27.05 0.14 1.57

The Greenrose Holding Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 1.57 1.77 2.38 9.76

STU:50U vs STLY, BLMS, WECT: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, The Greenrose Holding Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Greenrose Holding Co Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, The Greenrose Holding Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where The Greenrose Holding Co's Debt-to-Equity falls into.


STU:50U
22GF Score
The Greenrose Holding Co STU:50U
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The Greenrose Holding Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

The Greenrose Holding Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(96.161 + 0) / 61.138
=1.57

The Greenrose Holding Co's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(133.64 + 9.669) / 14.678
=9.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 9.76 mean?
The Greenrose Holding Co (STU:50U) has a Debt-to-Equity of 9.76 as of Sep. 2022. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on The Greenrose Holding Co and its competitors.
Is The Greenrose Holding Co's Debt-to-Equity too high?
The Greenrose Holding Co's current Debt-to-Equity is 9.76. The Drug Manufacturers industry median Debt-to-Equity is 0.28. The Greenrose Holding Co's value of 9.76 is 3385.7% above this industry median. Overall, The Greenrose Holding Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does The Greenrose Holding Co's Debt-to-Equity compare to STLY and BLMS?
The Greenrose Holding Co's Debt-to-Equity of 9.76 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.28. The Greenrose Holding Co's value of 9.76 is 3385.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Greenrose Holding Co's current Debt-to-Equity of 9.76 is 3385.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on The Greenrose Holding Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Greenrose Holding Co's current Debt-to-Equity is 9.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Greenrose Holding Co stock overvalued right now?
The Greenrose Holding Co (STU:50U) has a current Debt-to-Equity of 9.76. The current Debt-to-Equity is 9.76 and 3385.7% above the Drug Manufacturers industry median of 0.28. The Greenrose Holding Co's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For The Greenrose Holding Co (STU:50U), the current Debt-to-Equity is 9.76 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The Greenrose Holding Co Business Description

Other Exchanges GNRUQ:USA
Address 111 Broadway, Amityville, NY, USA, 11701
The Greenrose Holding Co is engaged in the manufacture and processing of cannabis in the adult-use and medical cannabis marketplace in Connecticut and Arizona.
22GF Score

Get the complete analysis for STU:50U

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.36
Price